Full-Time

Oncology Key Account Manager

Southeast

Updated on 8/21/2026

Deadline 10/31/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$146.3k - $211.3k/yr

New Orleans, LA, USA + 4 more

More locations: Nashville, TN, USA | Birmingham, AL, USA | Jackson, MS, USA | Atlanta, GA, USA

In Person

Field-based role requiring approximately 50% travel.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Sales
CRM
Electronic Health Records (EHR)
Marketing
Business Analytics
Financial Modeling

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • A B.A. or B.S. degree is required.
  • At least 4 years of relevant work experience, including healthcare sales or account management experience, is required.
  • The candidate must be located in the assigned geography or account region.
  • The candidate must have a valid driver's license and be willing to travel approximately 50% of the time.
  • The role requires the ability to build and maintain strategic account relationships and coordinate cross-functional teams.
Responsibilities
  • Build and maintain relationships with high-strategic-value community and health system or integrated delivery network accounts to drive Sarclisa adoption and business growth.
  • Develop in-depth knowledge of assigned customer accounts, including strategic goals, value drivers, access stakeholders, business metrics, and emerging needs.
  • Develop, execute, and maintain strategic account plans, including matrix-team planning, execution, and influencer mapping.
  • Integrate customer business segmentation into product objective planning and execution.
  • Support clinical, economic, and operational advocacy, including gaining key opinion leader endorsement and ensuring coverage on provider pathways, electronic medical records, and formularies.
  • Understand pull-through hurdles, organizational structures, customer ways of working, and cross-functional or departmental coordination needs.
  • Execute cross-functional launch planning.
  • Develop an understanding of contracting and product-access processes, bid and request-for-proposal workflows, stakeholders, financial models, and clinical evaluation models.
  • Serve as the point of contact for contracting and pricing agreements with owned accounts.
  • Develop and deepen strategic partnerships with oncology C-suite executives and population health decision makers.
  • Profile and perform targeted PIE engagements with top community and health system or integrated delivery network accounts in preparation for launch.
  • Support contract execution and pull-through at select health system accounts as applicable.
  • Co-create innovative partnership opportunities and solutions with key customers by aligning company and customer needs.
  • Coordinate with marketing, sales, and access teams on account strategy development and business planning.
  • Lead matrix teams without direct authority.
  • Collaborate with sales, medical, and marketing teams to align strategies.
  • Guide field-team engagement with customer accounts and support seamless execution.
  • Ensure execution of commercial strategies and account plans.
  • Communicate customer feedback to the organization.
  • Monitor market trends, competitor activities, and customer needs, and provide insights to internal teams.
Desired Qualifications
  • An advanced degree is preferred.
  • At least two years of current or recent key account management experience in oncology, working with population health decision makers and other access influencers, is preferred.
  • Effective leadership skills to elicit collaboration, coordination, and innovative thinking across cross-functional partners.
  • Enterprise-level entrepreneurial thinking.
  • A consultative mindset for effective and creative problem solving focused on customer needs.
  • Strong communication, presentation, and negotiation skills.
  • The ability to promote and lead with direct, honest, and supportive communication.
  • The ability to develop organizational capabilities while influencing others.
  • The ability to lead and inspire others in highly ambiguous and complex situations.
  • A commitment to improving oneself, the immediate team, and the broader oncology community.
  • Strong organization, dependability, self-motivation, and the ability to use planning tools in a fast-paced environment.
  • The ability to use effective professional communication to cultivate strong working relationships with internal and external colleagues.
  • Flexibility in approach to people and situations.
  • Device launch experience.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 17.8%; Dupixent topped €5.2 billion for the quarter.
  • July 30 upgraded 2026 guidance to around 10% sales growth, with higher EPS.
  • August 4 MenQuadfi infant approval widens vaccine reach; Nexviazyme's June phase 3 readout strengthens pipeline.

What critics are saying

  • Dupixent faces tougher H2 2026 comparisons, threatening growth after the €5.2 billion quarter.
  • Cenrifki carries liver injury risk; strict monitoring can slow adoption and invite liability.
  • Dupixent concentration and Regeneron's November 2024 lawsuit threaten Sanofi's core growth engine.

What makes Sanofi unique

  • Dupixent and partnered launch engine generate repeatable immunology cash flows across geographies.
  • Sanofi converted 2026 approvals for Sarclisa Escena, Wayrilz, and Cenrifki into launches.
  • Paulo Fontoura's September 1 R&D mandate centralizes translational science and regulatory execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.

Associated Press
Jul 10th, 2026
Sanofi's Sarclisa Escena approved in US as first anticancer drug delivered via on-body injector

The US Food and Drug Administration has approved Sanofi's subcutaneous Sarclisa Escena for treating multiple myeloma, making it the first anticancer treatment administered through an on-body injector. The therapy uses Enable Injections' CirCLIQ device, which delivers the drug automatically with a retractable 30g needle. The approval was supported by the IRAKLIA phase 3 study, which demonstrated that Sarclisa Escena delivered via the on-body injector provided similar efficacy and safety compared to intravenous infusion, with significantly shorter treatment time and fewer infusion-related reactions. The study showed a 71.1% objective response rate in patients with relapsed or refractory multiple myeloma. More than 70,000 patients worldwide have been treated with Sarclisa-based regimens. The on-body injector aims to reduce physical burden on healthcare providers whilst offering patients greater convenience during treatment.

Yahoo Finance
Jul 5th, 2026
Sanofi appoints Paulo Fontoura as R&D chief to accelerate pharma pipeline transformation

Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective 1 September. Based in Paris, Fontoura will oversee the company's innovation engine, spanning research, translational medicine, clinical development, and regulatory affairs. He succeeds Dr Houman Ashrafian, who is leaving to pursue new opportunities. Fontoura brings over 25 years of experience across academic medicine, translational science, and pharmaceutical innovation. The appointment comes as Sanofi drives an R&D transformation whilst progressing its pipeline across multiple therapeutic areas. Separately, MacroGenics confirmed it will receive $24.5 million in regulatory milestone payments from Sanofi following FDA accelerated approval of TZIELD to delay decline in endogenous insulin production in children. Sanofi is a global biopharmaceutical company focusing on immunology, rare diseases, and oncology.